Mayo Clinic, Rochester, Minnesota.
Arthritis Rheumatol. 2016 Sep;68(9):2290-9. doi: 10.1002/art.39686.
To investigate clinical and pathologic aspects of IgG4-related disease (IgG4-RD) in non-Asian populations.
We conducted a retrospective review of the medical records of patients with IgG4-RD who presented to an academic medical center from January 1994 to September 2012.
Among 166 patients identified, the median age at diagnosis was 61 years (interquartile range [IQR] 49-70 years), 75% were male, and 80% were white. The median number of organs involved was 2 (IQR 2-3). When organs were grouped according to anatomic system, the hepatopancreaticobiliary system was most commonly involved (77%). The median highest serum IgG4 level during the clinical course was 215 mg/dl (IQR 122-466). Forty-three patients (26%) had a normal serum IgG4 level. Seventy-nine pathology specimens were available for immunostaining. The median number of IgG4+ cells was 37 (IQR 25-82) per high-power field, with an IgG4+:IgG+ ratio of 0.50 (IQR 0.32-0.68). Among 151 patients who received medical therapy, 72 (48%) received steroid-sparing agents because of relapse, recurrence, or corticosteroid intolerance. Of the 66 patients who were newly diagnosed, started on corticosteroid monotherapy as the initial treatment, and followed up at our institution, 30 (45%) experienced relapse or recurrence despite an initial favorable response. The number of organs involved had a significant impact on time to relapse or recurrence, with a hazard ratio of 1.48 (95% confidence interval [95% CI] 1.12-1.93) (P < 0.01) in multivariate analysis. The standardized incidence ratio of malignancy was 4.5 (95% CI 1.5-7.5).
IgG4-RD is a multisystem disorder that commonly affects older men and has a propensity for relapse, recurrence, and malignancy.
研究非亚洲人群 IgG4 相关疾病(IgG4-RD)的临床和病理特征。
我们对 1994 年 1 月至 2012 年 9 月期间在一家学术医疗中心就诊的 IgG4-RD 患者的病历进行了回顾性分析。
在确定的 166 例患者中,中位诊断年龄为 61 岁(四分位距 [IQR] 49-70 岁),75%为男性,80%为白人。中位受累器官数为 2 个(IQR 2-3)。根据解剖系统对器官进行分组时,肝胆胰系统最常受累(77%)。在整个病程中,血清 IgG4 最高水平的中位数为 215mg/dl(IQR 122-466)。43 例(26%)患者的血清 IgG4 水平正常。有 79 份病理标本可进行免疫组化染色。每个高倍视野中 IgG4+细胞的中位数为 37(IQR 25-82),IgG4+/IgG+比值为 0.50(IQR 0.32-0.68)。在 151 例接受药物治疗的患者中,因复发、再发或皮质类固醇不耐受,72 例(48%)接受了类固醇保留药物治疗。在 66 例新诊断为 IgG4-RD、接受皮质类固醇单药初始治疗并在我院随访的患者中,尽管初始反应良好,但仍有 30 例(45%)出现复发或再发。受累器官数量对复发或再发时间有显著影响,多因素分析的危险比为 1.48(95%置信区间 [95%CI] 1.12-1.93)(P<0.01)。恶性肿瘤的标准化发病比为 4.5(95%CI 1.5-7.5)。
IgG4-RD 是一种多系统疾病,常见于老年男性,具有复发、再发和恶性肿瘤的倾向。